Epsilogen completes first-ever IgE antibody clinical trial
BioPharma Reporter
AUGUST 1, 2023
Epsilogen, a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, has published phase 1 data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.
Let's personalize your content